Molecular Cancer Therapeutics </>
</cgi/adclick/?ad=14561&adclick=true&url=http%3A%2F%2Fwww.aacr.org%2Fpage10063.aspx>
</cgi/adclick/?ad=15035&adclick=true&url=http%3A%2F%2Fwww.pwevent.com%2FAACR2007%2Findex.html>

HOME </> 	HELP </help/> 	FEEDBACK </cgi/feedback> 	SUBSCRIPTIONS
</subscriptions/> 	ARCHIVE </contents-by-date.0.shtml> 	SEARCH
</search.dtl> 	

*Institution: AACR* | Sign In via User Name/Password
</cgi/login?uri=%2Fmisc%2Fedboard.shtml>
------------------------------------------------------------------------

 

*/Molecular Cancer Therapeutics/ Information for Authors*

    Important Notice Regarding New Electronic Manuscript Submission
    System. /Molecular Cancer Therapeutics/ has changed to a new
    manuscript submission and peer review system.

        * Effective August 22, 2007, authors submitting new manuscripts
          to /Molecular Cancer Therapeutics/ are required to submit
          manuscripts online via *AACR SmartSubmit*
          (http://mct.msubmit.net). New submissions will be given a
          manuscript number higher than MCT-07-2000.

        * If you are submitting a REVISED version of a manuscript
          originally submitted via /Molecular Cancer Therapeutics’/
          previous system, Rapid Review, you must submit your revision
          via Rapid Review
          (http://www.rapidreview.com/AACR2/CALogon.jsp). Revised
          manuscripts will have a manuscript number lower than MCT-07-2000.

*Submit a Manuscript to /Molecular Cancer Therapeutics/: * 	
<http://mct.msubmit.net>

 

1. Categories of Publication <#a> 	  8. Terminology <#h>
2. Publication Policies <#b> 	  9. Correcting Proofs <#i>
3. Page Charges <#c> 	10. Publication Fees and Reprints <#j>
4. Submission Procedures <#d> 	11. Copyright and Permissions <#k>
5. Cover Features <#e> 	12. Advertisements <#l>
6. Format and Style <#f> 	13. Subscriptions and Business Inquiries <#m>
7. Abbreviations <#g> 	 


/Molecular Cancer Therapeutics/, a journal of the American Association
for Cancer Research, publishes significant, original studies,
minireviews, meeting reports, and commentaries on areas of basic
research that address the relationships between molecular structures,
biological activites, and the mechanisms of action of pharmacological
agents in the general area of cancer. Topics include experimental cancer
therapeutics, identification of molecular targets, targets for
chemoprevention, new models, cancer chemistry, drug discovery and
development, molecular and cellular pharmacology and pharmacogenomics,
surrogate markers and molecular classification of tumors, and
bioinformatics and computational molecular biology.

Papers are stringently reviewed, and only those that report results of
novel, timely, and significant research and meet high standards of
scientific merit are accepted for publication.

*1. CATEGORIES OF PUBLICATION*

The following types of articles will be considered for publication:

    (1) *Research Articles.* Reports of original research in one of the
    eight subject areas that are well documented, novel, and
    significant. The recommended length for research articles is fewer
    than 5,000 words, including 6 or fewer tables and figures, an
    abstract of 250 words or less, and no more than 50 references.
    Research articles are published an average of 60 days after their
    final acceptance.

    (2) *Minireviews.* Articles that review a timely subject important
    to cancer researchers. Minireviews must be as concise as possible
    and should not exceed 5,000 words of text with 3 or fewer tables and
    figures, an abstract of 200 words, and 75 or fewer references.
    Authors of unsolicited reviews should first submit an outline of the
    proposed review article for consideration by the Editors. All review
    articles, whether invited or not, will be subject to peer review.

    (3) *Letters to the Editor.* In the spirit of open scientific
    dialogue, the Editor-in-Chief invites the submission of
    correspondence that presents considered opinions in response to
    articles published in the journal. Letters to the Editor will be
    reviewed and, if found to meet the requisite publication criteria
    (scholarly commentary on a subject of import and interest to the
    broad readership, length appropriate to the content), the Letter may
    be sent to the author(s) of the originally published article and
    possibly to other interested parties for a response to be published
    in the same issue of the journal as the Letter. Correspondence
    concerning articles that have not been published in /Molecular
    Cancer Therapeutics/ will not be considered. Letters should have an
    8- to 10-word title that references the topic of the originating
    article, and Letters should not exceed 400 words, with 5 or fewer
    references and no tables or figures, unless agreed to by the Editor.

    (4) *Meeting Reports.* Brief reports on symposia and conferences in
    molecular cancer therapeutics should be submitted within 2 months of
    the meeting date in order to maintain their timeliness. Reports
    should consist of no more than 2,500 words and include a statement
    of the purpose(s) of the meeting, an integrated summary of the
    findings presented, and recommendations for future research. The
    names and affiliations of key speakers should be given in an
    Appendix. A meeting report should be a thoughtful, critical
    commentary that shows an appreciation of the connections among the
    various presentations and reveals the consensus, if any, that
    emerged from the meeting. Only those Meeting Reports that deal with
    topics of interest to the readership and that contain novel
    information and insights from the meeting are accepted for
    publication. Before submitting Meeting Reports for consideration,
    potential authors should send a letter to the Editor-in-Chief
    inquiring whether the topic meets the criteria for acceptance.
    Letters of inquiry should be sent to the Publications Office [fax:
    (215) 599-5646; e-mail: mct@aacr.org <mailto:mct@aacr.org>].

    (5) *Commentaries.* Brief papers invited by the Editors commenting
    on articles published in the journals.

Top <#top>

*2. PUBLICATION POLICIES*

Submission of a manuscript to /Molecular Cancer Therapeutics/ implies
that the author(s) of the paper understand and fully accept the policies
of the Journal as detailed in these "Information for Authors."

* No Prior or Subsequent Publication.* When a manuscript is submitted
for consideration, the authors should confirm in writing that neither
the submitted paper nor any similar paper, in whole or in part, other
than an abstract or preliminary communication, has been or will be
submitted to or published in any other scientific journal. Permission to
reproduce all or parts of articles published in AACR journals must be
sought from the AACR Publications Office [phone: (215) 440-9300; fax:
(215) 440-9354; e-mail: permissions@aacr.org <mailto:permissions@aacr.org>]

*Embargo Policy.* Once submitted, contributions cannot be discussed with
the media (including other scientific journals) until one week before
the publication date. The information in accepted articles is embargoed
from reporting by all media until 12:01 A.M. (EST) the date of issue.
Authors who discuss their work with the media during the week before
publication must ensure that the media representatives know the embargo
policy and the embargo date. Authors arranging their own publicity on
their articles are advised to notify the AACR Communications Department
in advance [phone: (215) 440-9300; fax: (215) 440-9410; e-mail:
communications@aacr.org <mailto:communications@aacr.org>].

* Authorship.* Who should be listed as an author is determined by the
authors or by policies at their institutions, or both. As a general
guideline, persons listed as authors should have contributed
substantially to:  1) the conception and design of the study,
acquisition of data, or analysis and interpretation of data;
 2) drafting the article or revising it for important content; and
 3) final approval of the version to be published. The corresponding
author is responsible for ensuring that all authors have agreed to be
authors and have agreed to the manuscript’s content and its submission
to the journal. If any changes are proposed to authorship after the
manuscript is submitted, including the order of author listing, the
corresponding author must provide the AACR Publications Department with
signed documentation that the authors involved agree to the changes.
/Molecular Cancer Therapeutics/ accepts no responsibility for deciding
matters of authorship.

*Image Acquisition and Analysis*

It is the authors’ responsibility to exercise discretion during data
acquisition, where misrepresentation must be avoided. Acquisition of
images for comparative purposes must be standardized. Specimen areas
should be selected which objectively represent the critical features
being presented. Images should be captured in a non-compressing format
such as .tif, or .bmp. Authors should retain their unprocessed images
and metadata files, as editors may request them to aid in manuscript
evaluation. If unprocessed data is unavailable, manuscript evaluation
may be delayed until the issue is resolved. Files which have been
adjusted in any way should be saved separately from the originals, also
in a non-compressed format. Compressing formats, such as .jpg, should
only be used for presentation of final figures, where requested, to keep
files sizes small for electronic transmission.

8 bit monochrome, or 24 bit RGB acquisition is acceptable for visual
documentation, but capture at higher bit depths is generally required
for fine analysis of intensity data. Only non-adjusted original files
should be used for analysis. If data is presented which includes
mathematical representations of pixel intensities and locations, the
original unprocessed files must be provided for review. A description of
the analysis preparation and techniques should be included in the
supplementary data.

*Image Manipulation*

The /American Association for Cancer Research/ allows that minimal image
adjustment is acceptable for publication in its journals; however, the
final image must remain representative of the original data. Adjustments
of brightness, contrast, or color balance are acceptable only if they
are applied to the whole image and as long as they do not obscure or
eliminate any information present in the original, including
backgrounds. Non-linear manipulation, such as “gamma” should only be
used to adjust the overall presentation of the image, to make sure
details are visible in the printed form. Alteration to specific features
within the image is generally not acceptable. Sub-forms of an image may
not be enhanced, obscured, moved or removed in relation to the larger
image.

Non-linear algorithms to enhance overall presentation such as background
subtraction, shading correction, sharpening, despeckling and flattening
may be acceptable, but disclosure of adjustment must be included in the
legend and the specific techniques must be described in the supplemental
data. Descriptions must include the original, unprocessed files for
comparison.

*Image Composites*

The grouping of images from different originals must be made explicit,
both by the arrangement of the figure (i.e., adding dividing lines) and
in the text of the figure legend. This also applies to multiple fields
taken from the same image (such as individual lanes combined from a
single electrophoresis gel), and separate images acquired with different
conditions. If dividing lines are not included, they will be added by
our production department, and may result in publication delays.

Figures presenting merged color images from fluorescence originals must
include the original single channel images used to make the merged file.
Original images captured as color files are acceptable, but grayscale
images are preferred, laid out in sequence as part of the figure.

Multiple images may be combined into a single photomontage when the area
of interest cannot be captured in a single image. In such a case, all
images which make up the montage must be captured using a standardized
method. Each smaller image must overlap its neighboring image by ¼ of
the shared field in each direction. The outer boundary of the combined
image must be clearly delineated with a line. Any post-processing must
be done to the total, combined montage. All original images must also be
submitted as supplementary data.

*Electrophoretic gels and blots*

Include positive and negative controls, as well as molecular size
markers, on each gel and blot. Provide a citation for previously
characterized antibodies. For antibodies less well characterized in the
system under study, we require a detailed characterization that
demonstrates not only the specificity of the antibody, but also the
range of reactivity of the reagent in the assay, which will be published
as supplementary data. Clearly separate vertically sliced gels that
juxtapose lanes that were not contiguous in the experiment or include a
line delineating the boundary between the gels.

The display of cropped gels and blots in the main paper is encouraged if
it improves the clarity and conciseness of the presentation. In such
cases, the cropping must be mentioned in the figure legend and the
supplementary information should include full-length gels and blots
wherever possible. These uncropped images should be labeled as in the
main text and placed in a single supplementary figure. The manuscript's
figure legends should state that “full-length blots/gels are presented
in Supplemental Figure X.”

    *

      Cropped gels in the paper must retain important bands.

    *

      Cropped blots in the body of the paper should retain at least six
      band widths above and below the band.

    *

      High-contrast gels and blots are discouraged, as overexposure may
      mask additional bands. Authors should strive for exposures with
      gray backgrounds. Multiple exposures should be presented in
      supplementary information if high contrast is unavoidable.
      High-contrast immunoblots should be surrounded by a black line to
      indicate the borders of the blot.

    *

      Describe all image acquisition tools and image processing software.

    *

      Document key image-gathering settings and processing manipulations
      in the Supplementary Data.

Top <#top>

*Microscopy*

The most important images should be made available to referees in images
that are at least 300 dpi at the size which they will be published.
Adjustments should be applied to the entire image. Threshold
manipulation, expansion or contraction of signal ranges and the altering
of high signals should be avoided. ‘Pseudo-coloring’ and nonlinear
adjustment (for example ‘gamma changes’) are only allowed if unavoidable
and must be disclosed. Include the following with the final revised
version of the manuscript for publication:

    *

      Include a magnification scale bar for each image.

    *

      In the Methods section, specify the type of equipment
      (microscopes/objective lenses, cameras, detectors) used.
      Acquisition software should also be specified, as well as a
      description of specialized techniques requiring large amounts of
      processing, such as confocal, deconvolution, 3D reconstructions,
      or surface and volume rendering.

    *

      In Supplementary Data, provide additional acquisition information
      for each image, including time and space resolution data (xyzt and
      pixel dimensions), image bit depth, experimental conditions such
      as temperature and imaging medium, and fluorochromes.

* Review Process.* All submitted manuscripts are assessed by a Senior
Editor, who makes the final recommendation on acceptance or rejection.
The Senior Editor will take one of the following steps:  1) directly
select peer reviewers for the manuscript or  2) determine that the
manuscript is not suitable for the journal and return it without peer
review. All reviewers and editors are required to adhere to ethical
guidelines that mandate strict confidentiality concerning all aspects of
the manuscript and its content. Manuscripts submitted for consideration
for publication are privileged communications, and the status of the
manuscript and details regarding it are available only to AACR editorial
staff, authors, and the editors and peer reviewers involved.

Submission of a manuscript implies acceptance by all authors of the
strict policy of the AACR that under no circumstances will the
identities, or information leading to the identities, of the Editors and
reviewers be revealed.

Every effort is made to render editorial decisions promptly. Authors who
have registered their manuscripts may check their status online
(http://mct.msubmit.net). Other inquiries should be made to the AACR
Publications Department via phone: (215) 440-9300; fax: (215) 599-5646;
or email: mct@aacr.org <mailto:mct@aacr.org> . /Collect telephone calls
from authors cannot be accepted./

* Conflict of Interest.* Journal policy requires that authors,
reviewers, and Editorial Board Members reveal to the Editor-in-Chief or
Senior Editors any relationships that they believe could be construed as
resulting in an actual, potential, or apparent conflict of interest with
regard to the manuscript submitted for review. Authors must disclose
this information in the covering letter accompanying their submission,
and reviewers are required to disclose this information upon agreeing to
review a manuscript. The existence of financial interests or other
relationships of a commercial nature is not necessarily regarded as
creating a conflict of interest. Rather, journal policy represents a
recognition of the many factors that can influence judgments about
research data and a desire to make as much information as possible
available to those reviewing the data. If in the judgment of the
Editor-in-Chief the information revealed does represent a potential
conflict of interest, notification concerning the relationship may be
published. If such action is deemed necessary, the authors will be
informed before publication.

* Availability of Materials.* It is understood that by publishing any
work in /Molecular Cancer Therapeutics/ the authors agree to make freely
available to other academic researchers any of the cells, clones of
cells, DNA, antibodies, or other material used in the research reported
and not available from commercial suppliers. The publication of articles
including new genes, proteins or crystallographic structures is
contingent on deposition of the accession number and/or structural
coordinates in a publicly accessible database. The reporting
requirements extend to the chemical structures of drugs, as well as
sequences of oligonucleotides used in antisense strategies and RNA. In
addition, AACR journals require the disclosure of chemical structures of
any unpublished synthetic, low molecular weight (<1,000 g/mol) chemical
compounds used as part of the described research (including clinical
studies in humans). These requirements are subject to amendment as the
need for disclosure changes with evolving technologies. Also, authors
may be required to make primary data available to the Editor-in-Chief if
the data needs to be examined to ensure validity.

* Depositing Data in Public Databases.* The AACR requires that authors
submitting manuscripts describing microarray data be prepared to supply
peer reviewers with the data in a format that conforms to the Minimum
Information About a Microarray Experiment (MIAME) guidelines of the
Microarray Gene Expression Data (MGED) society. These guidelines include
a checklist of information to be included with each new microarray
submission; the checklist is available online (
http://www.mged.org/Workgroups/MIAME/miame_checklist.html
<http://www.mged.org/Workgroups/MIAME/miame_checklist.html>). Authors
will also be required to deposit the data with either of two public
repositories: GEO (www.ncbi.nlm.nih.gov/geo/
<http://www.ncbi.nlm.nih.gov/geo/>) or Array Express
(www.ebi.ac.uk/arrayexpress <http://www.ebi.ac.uk/arrayexpress>) and to
have the accession numbers available to be published in the article.

Authors of manuscripts with new nucleotide or amino acids sequences are
asked to deposit the sequence information with GenBank (National Center
for Biotechnology Information, Building 38A, Rm. 8N-803, 8600 Rockville
Pike, Bethesda, MD 20894; phone: (301) 496-2475; fax: (301) 480-9241;
e-mail for information: info@ncbi.nlm.nih.gov
<mailto:info@ncbi.nlm.nih.gov>; e-mail for submission:
gb-sub@ncbi.nlm.nih.gov <mailto:gb-sub@ncbi.nlm.nih.gov>). Authors
outside of the United States may elect to deposit sequence information
in the European Molecular Biology Laboratory (EMBL) database (e-mail:
datasub@ddbj.nig.ac.jp <mailto:datasub@ddbj.nig.ac.jp>). The accession
numbers for deposited sequences will be published with the article.

Top <#top>

*3. SUBMISSION FEE AND PAGE CHARGES*

A *per-page charge* for each published page ($55 per page for the first
6 published pages; $75 per page for each additional published page) will
be levied on all manuscripts accepted for publication. It is understood
at the time of submission that the author(s) agree to pay this charge in
the event of publication. Please refer to the section titled
“Publication Fees and Reprints” for details. Under exceptional
circumstances, when no grant or other source of support exists, the
author(s) may apply to the Publisher at the time of submission for a
waiver of the page charges. All such applications must be countersigned
by an appropriate institutional official stating that no funds are
available for the payment of page charges.

 

*4. SUBMISSION PROCEDURES *

*Online Submission*

/Molecular Cancer Therapeutics/ requests that submissions be made
electronically through the *AACR SmartSubmit* system
(http://mct.msubmit.net). When you have completed the submission form,
you may submit your manuscript electronically. A comprehensive list of
acceptable file formats is available at http://mct.msubmit.net. Complete
details on how to submit or resubmit a manuscript can be found when you
log on to the *AACR SmartSubmit* to create an author account or on the
AACR Website (click here for Author Instructions
<http://www.aacr.org/Uploads/DocumentRepository/Journals/AACRSmartSubmit/author_instr.pdf>).
Once you have successfully submitted your manuscript online, you will
receive acknowledgement via e-mail.

Authors must register online whether they are submitting a manuscript
online or by regular mail.

*Registration*

When you register online, you will be asked to provide or select the
following:

    *

      Title of the manuscript.

    *

      Running title that does not exceed 50 characters in length to
      appear at the top of each printed page.

    *

      Full name and affiliations of all authors, complete with first and
      middle names or initials, but not academic degrees, and contact
      information for each.

    *

      A journal section that you believe to be the best match for your
      manuscript. Please note, however, that the final section
      assignments are made at the discretion of the editors.

    *

      The type of manuscript and an indication of whether or not the
      paper was invited.

    *

      At least one keyword from the pull-down list of terms to classify
      your manuscript. In addition to the keyword selection, you may
      also provide your own keywords in the text boxes provided.

    *

      Upload PDFs or other files for Supplemental Data (if necessary).

    *

      Cover letter typed into the box provided. Include a description of
      the novel and salient findings of the work, as well as any
      information not covered elsewhere in the submission form.

    *

      Authors should provide the names and affiliations of experts whom
      they feel are qualified to review their manuscript. Final
      assignment of the manuscript to peer-review, however, is made at
      the discretion of the Editors.

    *

      Abstract (not to exceed 250 words) for most types of articles (see
      Categories of Publication) typed into the box provided. Abstracts
      are often copied directly by the secondary services, so they
      should recapitulate in abbreviated form the purpose of the study
      and the experimental technique, results, and interpretations of
      the data. Include a synopsis of all pertinent data, but do not
      include references. Avoid abbreviations and acronyms.

    *

      Answers to questions about the manuscript, such as statement of
      authorship, notification of color reproduction costs, and
      disclosure of conflicts of interest.

Top <#top>

When you have completed the submission form, you may submit your
manuscript electronically. A comprehensive list of acceptable file
formats is available at http://mct.msubmit.net. Print out the copyright
transfer form [available for download at
http://www.aacr.org/pdf_files/journals/MCT_Copyright_Form.pdf] after you
have completed the submission process, have it signed by all of the
authors (if necessary, you can send copies of the form to the other
authors for signature and have them return the signed form to the
Editorial Office) and send it as quickly as possible, along with a copy
of the cover letter to: Molecular Cancer Therapeutics Editorial Office,
615 Chestnut St., 17th Floor, Philadelphia, PA, 19106. Keep a copy of
all materials, including the copyright transfer form for your records.
Please note that a manuscript cannot complete the review process until
the copyright form is received.

If you have successfully submitted your manuscript online, you will
receive acknowledgement via e-mail. If you will be submitting your
manuscript in hard copy, please send 2 copies of the cover letter,
manuscript, and figures, as well as a copy of the manuscript on disk or
CD, and a copyright form signed by all authors to the Molecular Cancer
Therapeutics Editorial Office, 615 Chestnut St., 17th Floor,
Philadelhphia, PA 19106.

*Revisions*

If you have been asked to revise your paper and you are ready to
resubmit it, log on to the *AACR SmartSubmit* system
http://mct.msubmit.net and, on your author homepage, click the Revised
Manuscript link of the manuscript you wish to resubmit. You will be
asked to review the information you originally submitted to confirm its
accuracy. In your cover letter, please be sure to provide a point by
point reply to the reviewers’ comments as well as a listing of the
changes made and page numbers where the changes appear.

When you have successfully resubmitted your manuscript, you will receive
acknowledgment via e-mail.

Please note that all authors on a paper will be required to complete
Conflict of Interest and Copyright Transfer forms prior to acceptance of
any manuscript.

The revised version of your manuscript may undergo another review if the
original submission required extensive changes or if the authors’
responses to the criticisms entail rebuttal rather than revision.
Authors of regular research articles are asked to submit revised
versions within 5–6 weeks from the notification of the decision on a
manuscript. The Editors acknowledge that a longer period might be needed
to make the revisions in some cases; however, authors must request an
extension by contacting the Publications Office or the resubmission will
be considered a new manuscript and it will be subject to all of the
conditions of an original submission.

*Appeals for Reconsideration*

Manuscripts that have been declined for publication will be reconsidered
only at the Editor-in-Chief’s or Senior Editor’s discretion. Authors who
wish to request reconsideration of a previously rejected manuscript
should send electronically to mct@aacr.org <”mailto:mct@aacr.org“> a
manuscript that has been revised in response to the criticisms along
with a covering letter describing the revisions. The manuscript
identification number of the previous submission should be referenced in
the covering letter. If the Editor-in-Chief or Senior Editor determines
that the paper should be reconsidered, you will be asked to submit it
electronically, and it may be assigned a new manuscript identification
number and date of receipt.

 

*5. COVER FEATURES*

The covers of /Molecular Cancer Therapeutics/ feature illustrations the
Editor-in-Chief selects from the articles scheduled for publication in
that issue. Authors whose articles are chosen for a cover feature will
be asked to provide a high-quality version of the selected illustration
as well as a brief legend (four to five sentences) describing the
significance of the image. In light of the rapid production schedule for
journal covers, authors are expected to provide the requested material
*within 3 days*.

Top <#top>

*6. FORMAT AND STYLE*

Papers are to be written in clear, grammatical English and must be typed
double-spaced. Papers that are not in /Molecular Cancer Therapeutics/
style or that are not in good idiomatic English may be returned to the
author without review. Laboratory jargon as well as terminology and
abbreviations not consistent with internationally accepted guidelines
should be avoided.

The AACR journals generally conform to usage guidelines in the following
publications: /Stedman's Medical Dictionary/ (Twenty-seventh Edition,
2000, Lippincott Williams & Wilkins, Baltimore, MD); /CBE Style Manual/
(Sixth Edition, 1994, published by the Council of Biology Editors, Inc.,
Northbrook, IL). For general guidance on manuscript preparation, consult
the documents issued by the International Committee of Medical Journal
Editors (www.icmje.org <http://www.icmje.org>).

Large data sets of peripheral significance to the main thesis of the
investigation will not be published in /MCT/ but may be published in the
Data Supplements section of /Molecular Cancer Therapeutics/ online.
Contact the AACR Publications Department for more information.
Supplementary data should be submitted for review with the manuscript.

Manuscripts should be arranged in the following order: title, author(s)
and complete name(s) and location(s) of institution(s) or
laboratory(ies), running title, key words, abbreviations list,
footnotes, text and references, tables, legends for all illustrations,
illustrations, and other material. Numbered and lettered sections in the
text should be avoided. Each table and illustration must be cited in
order in the text. Simple chemical formulas or mathematical equations
should be presented in a form that allows their reproduction in single
horizontal lines of type; more complicated mathematical formulas or
chemical structures difficult to set in type should be provided for
reproduction in the form of line drawings, glossy photographs, or
digital files (see “Illustrations” for more details).

* Title.* Write a brief, informative title limited, if possible, to
about 100 characters. It is important for literature retrieval to
include in the title the key words that identify the nature of the
subject matter, including, if applicable, the species on which the work
is done. Avoid expressions such as “Studies on . . . ” or “Observations
of . . . ”, and avoid chemical formulas or abbreviations. Also, do not
use Roman or Arabic numerals to designate that the paper is part of a
series (see section below on *Footnotes*).

* Authors and Affiliations.* Authors are urged to include their full
names, complete with first and middle names or initials. Academic
degrees should not be included. The names and locations of institutions
and the laboratories or names and locations of companies should be
given. If several institutions are listed on a paper, it should be
clearly indicated with which department and institution each author is
affiliated by using superscript numbers that correspond to each author's
affiliation.

Include the following footnotes to the title page (if applicable) in
this order:

    * Financial support, including the source and number of grants.

    * Full name, mailing address, and e-mail address (optional) of the
      person to whom reprint requests should be sent.

    * Other notes about the paper as a whole (whether part of a series,
      conflict of interest statements, etc.).

* Running Title.* A brief running title of about 50 characters should be
provided.

* Key Words.* On the title page, provide five key words identifying the
subject of your article.

*Abbreviations List.* In addition to explaining abbreviations at first
mention (see section on Abbreviations), authors should also list all
abbreviations used on the title page of the manuscript.

* Footnotes.* In most instances information should be presented in the
text, not in footnotes. If footnotes are necessary, use superscript
Arabic numerals consecutively throughout the text.

For footnotes to tables, see the section on *Tables*.

Top <#top>

* Abstract.* The abstract that appears at the beginning of the paper
should be concise, yet outline the content of the paper (see the
specifications for each type of article for abstract length). Because
abstracts are often copied directly by secondary services (such as
Medline, Chemical Abstracts, etc.), they should recapitulate in
abbreviated form the purpose of the study and the experimental
technique, results, and data interpretations. Data such as the number of
test subjects and controls, strains of animals or viruses, drug dosages
and routes of administration, tumor yields and latent periods, length of
observation period, and magnitude of activity should be included. Vague,
general statements such as ”The significance of the results is
discussed,” or “Some physical properties were studied,” are
uninformative and not acceptable. All important terms relevant to the
content of the paper should be incorporated into the abstract to assist
indexers in the derivation of key words. Abbreviations should be kept to
an absolute minimum; however, if they are needed, they must be explained
at first mention so the abstract can be understood independent of the
text. Do not cite references in the abstract.

* Introduction.* It is not necessary to cite all of the background
literature in the Introduction. Brief reference to the most pertinent
papers generally suffices to acquaint the reader with the findings of
others in the field and with the problem or question that the
investigation addresses.

* Materials and Methods.* Explanation of the experimental methods should
be brief but adequate for repetition by qualified investigators.
Procedures that have been published previously should not be described
in detail but merely cited in appropriate references. Only new and
significant modifications of previously published procedures need
complete exposition. The sources of special chemicals or preparations
used should be given along with their locations (city, state, and
country, if not the United States).

This Journal endorses the principles embodied in the Declaration of
Helsinki and expects that all investigations involving humans will have
been performed in accordance with these principles. In particular,
papers reporting human experimentation must include a statement that the
human investigations were performed after approval by an institutional
review board and in accordance with an assurance filed with and approved
by the Department of Health and Human Services, where appropriate. Also,
papers reporting biomedical research involving human subjects must
include a statement that informed consent was obtained from each subject
or subject's guardian. To obtain a copy of the Helsinki Declaration,
contact the World Medical Association, Bôite Postale 63, 01210,
Ferney-Voltaire Cedex, France, or acquire a copy from the WMA Website
(www.wma.net/e/policy/b3.htm <http://www.wma.net/e/policy/b3.htm>).

/Molecular Cancer Therapeutics/ is a staunch supporter of the most
humane treatment of animals in the conduct of scientific studies, and it
is expected that investigators will adhere to widely accepted national
standards such as the following:

    *

      The U.S. Public Health Service /Policy on Humane Care and Use of
      Laboratory Animals/, available from the Office of Laboratory
      Animal Welfare, National Institutes of Health, Department of
      Health and Human Services, RKLI, Suite 360, MSC 7982, 6705
      Rockledge Drive, Bethesda, MD 20892-7982, or online
      (http://grants.nih.gov/grants/olaw/olaw.htm#pol).

    *

      The United Kingdom Coordinating Committee on Cancer Research's
      “Guidelines for the Welfare of Animals in Experimental Neoplasia”
      (Second Edition, 1997) available online
      (http://www.ncrn.org.uk/csg/animal_guides_text.pdf). This report
      encourages researchers to “refine endpoints in experimental
      neoplasia and to disseminate best practice by publishing such
      improvements, to incorporate welfare statements in experimental
      protocols, and to report compliance with appropriate guidelines in
      publications.”

Only the results (particularly the photographic presentation of
experimental data) in which proper attention has been given to ethical
considerations toward animals will be published, and the AACR reserves
the right to reject papers that do not follow accepted standards.

* Results.* Include a concise summary of the data presented in tables
and illustrations. Excessive elaboration of data already given in tables
and illustrations should be avoided. The Results and Discussion sections
should be combined if, by so doing, space is saved or the logical
sequence of the material is improved.

* Discussion.* The data should be interpreted concisely without
repeating material already presented in the Results section. Speculation
is permissible, but it must be well founded, and discussion of the wider
implications of the findings is encouraged.

* References.* Number the references in the order of their first mention
in the text; cite only the number assigned to the reference. The
reference list should be limited to only those citations essential to
the presentation. When comprehensive review articles are available,
citation of the review article is preferred to citing many separate
references.

Before submission of the paper, authors should verify the accuracy of
all references and check that all references have been cited in the
text. /Molecular Cancer Therapeutics/ reference style follows that of
the /Uniform Requirements for Manuscripts Submitted to Biomedical
Journals/, which can be found on the website of the National Library of
Medicine (www.nlm.nih.gov/bsd/uniform_requirements.html
<http://www.nlm.nih.gov/bsd/uniform_requirements.html>).

Use the Medline journal abbreviations and follow the reference style
shown on the Website noted above, with the following exceptions:

    *

      List all authors when there are six or fewer. If there are more
      than six authors, list the first three followed by /et al./

    *

      Do not use a period (full stop) at the end of the journal title or
      abbreviation.

Top <#top>

*References Examples*

Gray PJ Jr, Bearss DJ, Han H, et al. Identification of human polo-like
kinase 1 as a potential therapeutic target in pancreatic cancer. Mol
Cancer Ther 2004;3:641-6.

Yuspa SH, Hennings H, Roop D, Strickland J, Greenhalgh DA. Genes and
mechanisms involved in malignant conversion. In: Harris CC, Liotta LA,
editors. Genetic mechanisms in carcinogenesis and tumor progression. New
York: Wiley-Liss; 1990. p.115-26.

/ Papers in press./ Papers in press may be listed among the references
provided a journal name and tentative year of publication can be verified.

/ Unpublished material./ Papers in preparation or submitted for
publication, unpublished data, and personal communications should be
cited in a footnote, /not/ in the Reference section. The names of all
authors should be given, along with the title of the paper, if possible.
Authors should secure permission from the authors of unpublished
material to cite it.

* Addenda.* Data acquired after acceptance of the paper, by the authors
themselves or by others, cannot be added to the text. Such addenda are
subject to approval by the Editor-in-Chief and could result in delay of
publication. Addenda should be kept extremely brief.

*Tables.* Tabular material should not duplicate data already presented
in detail in the text, nor should tables be only lists. A table should
compare values. If you are putting data in a table, summarize the data
in the text and reference the table. Unnecessary columns of data that
can easily be derived from other data in the table should not be
included. Large groups of individual values should be avoided; instead,
these should be averaged and an appropriate designation of the
dispersion such as standard deviation or standard error included.

/ Authors are obliged to indicate the significance of their observations
by appropriate statistical analysis./

Every table /must/ have a descriptive title and enough explanatory
information so the reader can understand the data without reference to
the text. Each column must carry an appropriate heading and, if
measurements are given, the units should be given with the column
heading. Number tables using Arabic numerals; table footnotes should be
indicated with standard footnote signs: *, †, ‡, §, ||, **, ††, etc.
Include a Note after the footnotes in which all abbreviations used in
the table that have not been used in the text are explained.

* Illustrations.* Line drawings (graphs) or halftone illustrations
(photographs, photomicrographs, electrophoretic patterns) are designated
as figures. Figures should be used when salient points need illustration
for better comprehension by the reader.

Figures should be labeled on the face of the illustration with the first
author's name and the figure number on the front of the figure.
Multipart figures should be limited to no more than 4 panels. For
halftones, the top of the figure should also be noted.

All figures must have legends that briefly describe the data shown;
details given in the text of the paper should not be repeated. Stains
and original magnifications should be listed where applicable. Each
legend should adequately identify all parts, symbols, abbreviations,
mathematical expressions, abscissas, ordinates, units, and reference
points on the figure. Abbreviations explained in the text of the article
need not be re-explained in the figure legend.

When graphs are reduced to the size of a single column, the text on them
must be no smaller than 6-point type and no larger than 12-point type,
and all symbols must be discernible. Avoid gray shading or screening in
graphs, particularly bar graphs. Avoid using very thin, broken, or
dotted lines.

Figure symbols should be defined in the legend. Only those common
symbols for which the printer has type should be used. Lines connecting
the symbols should not extend beyond the data points.

Graphs should be ruled off close to the area occupied by the curve, and
abscissas and ordinates should be clearly marked with appropriate units.
Explanations of the coordinates should not extend beyond the respective
lines. Do not box-in graphs with top and right-hand frame lines unless
these are essential for reference. Titles printed outside the confines
of the drawing waste space; all of this information should be included
in the legend. Also, to conserve space those curves that may
appropriately appear together should be included in a single graph.

Halftones that must appear together for comparison should be grouped
under one figure number with each section given sequential letters (A,
B, C) in the upper left-hand corner on the face of the illustration.
Composite figures may be mounted on a plate, with the sections butted
together and tooling (thin lines) placed between the parts of the
figure. For optimal reproduction, the contrast among photographs on a
plate should be consistent. The overall dimensions of photographs on a
plate should not exceed 18.4 x 22.4 cm (7 1/4 x 9 inches).

Symbols, arrows, or letters used in photomicrographs should contrast
with the background. /Internal scale markers should be included on the
photographs themselves or the original magnification should be given in
the legend because it may be necessary to reduce the figures./

*Color Photographs.* Authors are encouraged to submit color
illustrations. The expense of reproducing color photographs must be
offset partially by the author. The cost of color reproduction charged
to authors is $500 per color figure. Figures mounted together
(multi-part figures) are considered one figure. Multi-part figures
should be limited to no more than 4 panels. Please note that the author
is responsible for submitting prints that are of sufficient quality to
permit accurate reproduction, and for approving the final color proof.
/Molecular Cancer Therapeutics/ assumes no responsibility for the
quality of the photograph as it appears in the journal.

Top <#top>

*7. ABBREVIATIONS *

Abbreviations are in general a hindrance to readers in fields other than
that of the author(s), to abstractors, and to scientists whose primary
language is not English. Authors should limit their use to an absolute
minimum. Use only abbreviations for terms that are better known as an
abbreviation-such as DNA-or use widely accepted abbreviations. Single
words should not be abbreviated-for example, melanoma, folate,
vincristine. Abbreviations are not to be used in titles, but running
titles may carry abbreviations for brevity. All abbreviations must be
explained at first mention unless the term is better known as an
abbreviation (see Standard Abbreviations).

Authors should follow the recommendations of the IUPAC-IUB Commission on
Biochemical Nomenclature.

Standard Abbreviations. Authors may use, without definition,
abbreviations of units of measure when they are used with units
(1.5 cm). The following are examples of standard abbreviations that may
be used in the text, without explanation:

 
ABVD* 	Adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine
ADP, dADP 	 
AMP, dAMP 	 
AATP, dATP 	 
bp 	base pair(s)
CDP, cCDP 	 
CMP, cCMP 	 
CNBr 	cyanogen bromide
cDNA 	complementary DNA
CoA 	coenzyme A
CTL 	cytotoxic T-lymphocyte
CTP, dCTP 	 
cyclic ADP 	adenosine 3[prime],5[prime]-diphosphate
cyclic AMP 	adenosine 3[prime],5[prime]-monophosphate
DEAE 	diethylaminoethyl
DNA, cDNA 	 
EDTA 	ethylenediaminetetraacetic acid
EGTA 	ethyleneglycotetraacetic acid
EtOH 	etomidate
GDP, dGDP 	 
GMP, dGMP 	 
GTP, dGTP 	 
HEPES 	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid or
  	/N/-2-hydroxyethylpiperazine-/N/[prime]-2-ethanesulfonic acid
IDP, dIDP 	 
IMP, dIMP 	 
IR 	infrared
ITP, dITP 	 
MOPP 	mechlorethamine, oncovin (vincristine), procarbazine, and prednisone
NAD^+ 	NADH
NADP^+ 	nicotinamide adenine dinucleotide phosphate (oxidized form)
NADPH 	nicotinamide adenine dinucleotide phosphate (reduced form)
PBS 	phosphate-buffered saline
PIPES 	1,4-piperazinediethanesulfonic acid
POPOP 	1,4-bis[Isqb]2-(5-phenyloxazolyl)[rsqb]benzene
PPO 	2,5 diphenyloxazole
Pi, Ppi 	orthophosphate, pyrophosphate
R_f 	retardation factor
RFLP 	restriction fragment length polymorphism
RIA 	radioimmunoassay
RKO cells 	 
RNA, aRNA, mRNA, nRNA, tRNA 	 
Rnase, DNase 	 
RPMI 	Roswell Park Memorial Institute
rRNA 	spell out as "Ribosomal RNA" in title only
SD 	standard deviation
SDS 	sodium dodecyl sulfate
SDS-PAGE 	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SEM 	standard error of the mean
SSC 	standard saline-citrate
SV40 	Simian Virus 40
TBS 	Tris-buffered saline
	 
TDP, dTDP 	 
TEAE 	triethylaminoethyl
TMP, dTMP 	 
TTP, dTTP 	 
Tris 	tris(hydroxymethyl)aminomethane and tris(hydroxymethyl)methylamine
UDP, dUDP 	 
UMP, dump 	 
UTP, dUTP 	 
USP units 	 
USPHS 	United States Public Health Service
UTP 	uridine 5c-triphosphate
UV 	ultraviolet
w/v 	weight per volume
w/w 	weight for weight

Top <#top>

*8. TERMINOLOGY*

Use the approved terms and abbreviations for chemical substances
recommended by the International Union of Pure and Applied Chemistry
(IUPAC). Comprehensive recommendations on nomenclature are available
online (www.iupac.org/dhtml_home.html
<http://www.iupac.org/dhtml_home.html>). Recommended nomenclature for
biomedical and physical sciences can be found in /Scientific Style and
Format/, Sixth Edition, Council of Biology Editors (now the Council of
Science Editors), 1994 (Available from: www.councilscienceeditors.org
<http://www.CouncilScienceEditors.org>).

Authors should use the Recommended Name given in /Enzyme Nomenclature
1992: Recommendations of the Nomenclature Committee of the International
Union of Biochemistry on the Nomenclature and Classification of Enzymes/
(Academic Press, Inc., Orlando, FL, 1992). In some cases the Systematic
Name or the reaction catalyzed should also be included. It is strongly
recommended that the Enzyme Commission number be stated at first
mention. Supplements to this work are available online
(www.chem.qmul.ac.uk/iubmb/enzyme
<http://www.chem.qmul.ac.uk/iubmb/enzyme>).

Designations for mouse strains should conform to the /Rules and
Guidelines for Genetic Nomenclature in Mice/, from the International
Committee on Standardized Genetic Nomenclature for Mice (Mouse Genome;
1994:92: vii-xxxii) and available online
(www.informatics.jax.org/mgihome/nomen.shtml
<http://www.informatics.jax.org/mgihome/nomen/old_strain.shtml>).

Generic names of drugs are preferred with the brand name included at
first mention only to identify new components that may not be recognized
by their generic name. If a non-U.S. proprietary name is used, the name
of the comparable U. S. product should be given. When there is no
generic name for a drug, authors should give the chemical name or
formula or a description of the active ingredients.

Authors should refer to the formally adopted generic names listed in the
current edition of USAN and the USP Dictionary of Drug Names.

*9. CORRECTING PROOFS*

Authors will receive page proofs electronically. Alterations in proof
are costly and, if extensive, can lead to publication delays. Authors
will be charged for excessive changes in proof not due to printer's
errors. The Editors retain the prerogative to question alterations that
do not follow the journal's style and alterations that might affect the
scientific content of the paper. Authors should check their proofs
carefully to ensure that all special characters converted properly from
the electronic files submitted.

/Page proofs should be returned to the AACR Publications Department
within 24 hours of receipt via an overnight delivery service. Proofs not
received by the deadline will be published without the authors'
corrections or publication will be delayed to a later issue./ Authors
who will not be available to read their proofs should appoint someone to
handle the proofreading in their absence.

*10. PUBLICATION FEES AND REPRINTS*

Publication fees for /Molecular Cancer Therapeutics/ articles include a
per-page charge of $55 for the first 6 published pages and $75 for each
additional published page. Articles containing color figures are also
subject to a color reproduction charge of $500 per figure. Figures
converted to black and white at the proof stage will *not* have this fee
waived. Fees must be agreed to before the article is accepted and are
also itemized on the reprint order form that is sent to authors with
their proofs. If this form is not in your proof package, the AACR
Publications Department should be contacted immediately [phone: (215)
440-9300; fax: (215) 599-5646].

The reprint order form must be completed and returned two weeks before
publication, even if reprints are not desired, because payment
information for the publication fees is required. Failure to return the
form with this information will delay publication of your article.

Prepayment for publication fees and, if desired, for reprints, can be
made in the form of a check (in U.S. dollars, drawn on a U.S. bank),
signed institutional purchase order, or credit card (VISA, Mastercard,
American Express) information supplied on the reprint order form, which
serves as a proforma invoice. Return the order form and payment made
payable to: American Association for Cancer Research, P.O. Box 631060,
Baltimore, MD 21263-1060.

Reprints are shipped approximately 2 weeks after publication of the
journal. Allow extra time for delivery.

After publication, the cost of reprints for articles that contain color
is much more expensive than before publication, and this cost will be
estimated on an individual basis. For such an estimate or if you have
any other inquiries regarding reprints, please contact Cadmus Journal
Services Reprint Department [phone: 1-800-407-9190 or (410) 819-3992;
fax: (410) 820-9765].

A footnote should be supplied indicating to which author reprint
requests should be addressed.

Top <#top>

*11. COPYRIGHT AND PERMISSIONS*

Under the copyright law (PL 94-553), which became effective January 1,
1978, copyright for works is vested in the author from the moment of
creation and remains the property of the author until legally
transferred. Therefore, authors who wish to publish in /Molecular Cancer
Therapeutics/ must formally transfer copyright to the AACR. It is
understood by this transfer that authors relinquish all exclusive rights
of copyright ownership, including without limitation all rights of
reproduction, derivation, distribution, sale, and display of the work,
in whole or in part, in any and all forms of media now or hereafter
known. However, the journal will routinely allow authors (or others,
with permission) to include select parts of a copyrighted article in
reviews, books, or subsequent papers, upon written request to the AACR
Publications Department via e-mail at permissions@aacr.org
<mailto:permissions@aacr.org>, via fax at (215) 440-9354, or via regular
mail or air mail at AACR Permissions Dept., 615 Chestnut Street, 17th
Floor, Philadelphia, PA, USA, 19106. Persons requesting permission
should use the form available online (click here for the *Permission
Form* Word document
<http://www.aacr.org/Uploads/DocumentRepository/Journals/permissionformrev.doc>).
Requests to reproduce an article in its entirety will be considered on
an individual basis and permission may be granted contingent upon
payment of an appropriate copyright fee. All reproduction requests must
include a brief description of intended use and a stamped,
self-addressed envelope.

It is understood in conveying copyright that the authors have not
published this material elsewhere, either whole or in part (except in
abbreviated form as a preliminary communication), and that they have
neither concluded previous negotiations nor initiated pending
negotiations for copyright of this material.

The duly authorized agent of a commercial firm or commissioning
organization must sign our copyright transfer form if the author
prepared the article as part of his or her official duties as an employee.

The federal government has determined that it has a nonexclusive right
to publish or republish material developed from work performed under
federal grant-supported projects. Therefore, copyrights for such works
are subject to this restriction. Since the federal government does not
recognize private copyright for work performed by its employees as part
of their official duties, the journal will accept papers from government
laboratories without copyright transfer, provided that the authors abide
by the same provisions required of other authors and sign the
appropriate section of our copyright transfer form.

Appropriate forms for transfer of copyright must be received with
manuscript submissions. Persons requesting a copyright transfer should
either use the form available online (click here for the *MCT Copyright
Transfer Form* PDF
<http://www.aacr.org/Uploads/DocumentRepository/Journals/MCT_Files/mct_copyright_form.pdf>)
or request a form from the AACR Publications Department. /The journal
will not publish a paper unless the form is properly filled out and
signed by all authors./

Articles produced entirely by federal government employees are
understood to be in the public domain and may be copied without
restriction or payment of a fee. Copies of other articles in /Molecular
Cancer Therapeutics/ may be made for personal or internal use, provided
that the copier pay a per-copy fee of $15 through the Copyright
Clearance Center, Inc. This Center is a nonprofit organization through
which individuals and institutions may reimburse a copyright owner for
photocopying of journal articles beyond what is defined as "fair use" in
Sections 107 and 108 of the Copyright Revision Act of 1978. The
appearance of a fee code on the back of the title page of each issue
indicates that the AACR, as copyright owner, has consented to this
procedure. [Between June 1978 and August 1983, a fee code appeared on
the first page of all articles for which the AACR owned the copyright.
For those issues, it is understood that any articles that did not carry
this code are in the public domain.]

Those who wish to photocopy articles for which the AACR holds the
copyright should report the title of the journal, the month and year of
publication, the initial page number of the article, the number of
copies made, and the appropriate fee code to: Copyright Clearance
Center, Inc., 222 Rosewood Drive, Danvers, MA 01923; phone: (508)
750-8400; fax: (508) 750-4744. Remittances may be sent to the Center at
the time of reporting or the Center will bill the user on a monthly
basis. Deposit accounts and prepayment plans may also be arranged.

Top <#top>

*Important Notice Regarding the NIH Public Access Policy*

Authors of manuscripts reporting NIH-funded work that are accepted after
May 2, 2005 are granted permission to deposit their unedited and
unformatted manuscripts on the National Library of Medicine's
PubMedCentral database, should they wish to do so. AACR grants such
permission, without formal request, subject to the following conditions:

    *

      Only the *accepted manuscript* is deposited, not the edited and
      formatted paper as published in the journal.

    *

      Authors stipulate that PubMedCentral may release the paper for
      public access *1 year after its print publication*, not sooner.

    *

      Authors *acknowledge the published source* of the material.

 

*12. ADVERTISEMENTS*

Advertisement insertion orders and copy must be received approximately
5 weeks prior to the date of the issue in which the advertisement is to
be published. The journal is mailed approximately 5 days before the date
of issue; issues are dated the 1st and the 15th of each month. Inquiries
regarding advertising should be directed to: M.J. Mrvica Associates,
Inc., 2 West Taunton Ave., Berlin, NJ 08009; phone: (856) 768-9360; fax:
(856) 753-0064; email: dmather@mrvica.com <mailto:dmather@mrvica.com>.

 

*13. SUBSCRIPTIONS AND BUSINESS INQUIRIES*

/Molecular Cancer Therapeutics/ is published once a month, one volume
per year, by the AACR. Except for members of the Association, all
subscriptions are payable in advance to AACR, Subscription Office, P.O.
Box 11806, Birmingham, AL 35202 [phone: 1-800-633-4931 or (205)
995-1567; fax: (205) 995-1588], to which all business communications,
remittances (in United States currency or its equivalent), and
subscription orders should be sent. In Japan, send orders and inquiries
to (sole agent): USACO Corporation, Tsutsumi Bldg., 13-12, Shimbashi
1-chome, Minato-ku, Tokyo 105, Japan; phone: (03) 502-6471. The regular
annual subscription price of /Molecular Cancer Therapeutics/ for members
of the AACR is $70. Individuals who are not AACR members may subscribe
to Volume 6 (2007) of /Molecular Cancer Therapeutics/ at the rate $115
U.S./$160 foreign. Subscriptions to /Molecular Cancer Therapeutics/ are
also available to institutions at the rate of $400 U.S./$470 foreign.
Canadian subscribers should add 7% GST.

Changes of address should be sent 60 days in advance and include both
old and new addresses. /Member subscriber/s should send changes of
address to: AACR Member Services, 615 Chestnut Street, 17th Floor,
Philadelphia, PA 19106-4404. Nonmember subscribers should send changes
of address to: AACR Subscription Office, P.O. Box 11806, Birmingham, AL
35202.

*No responsibility is accepted by the Editors, by the AACR, Inc., or by
Cadmus Journal Services for opinions expressed by the contributors or
for the content of advertisements.*

Top <#top>

------------------------------------------------------------------------
HOME </> 	HELP </help/> 	FEEDBACK </cgi/feedback> 	SUBSCRIPTIONS
</subscriptions/> 	ARCHIVE </contents-by-date.0.shtml> 	SEARCH
</search.dtl> 	

Cancer Research <http://cancerres.aacrjournals.org> 	Clinical Cancer
Research <http://clincancerres.aacrjournals.org>
Cancer Epidemiology Biomarkers & Prevention
<http://cebp.aacrjournals.org> 	Molecular Cancer Therapeutics
Molecular Cancer Research <http://mcr.aacrjournals.org> 	Cell Growth &
Differentiation <http://cgd.aacrjournals.org>

Copyright © 2007 by the American Association for Cancer Research.
</misc/terms.shtml>

